Evidence map›Paper›PMID 41365977›Full record

ArticleNature communications2025

Prime editing of the β

Desirée Böck, Lisa Tidecks, Maria Wilhelm, Waleed ElGrawani, Sian Duss, Chiara Trevisan, Dalila Vena, Anna Maria Reuss, Lucas Kissling, Matteo Ranucci and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Desirée Böck *Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland. desiree.boeck@hest.ethz.ch.
Lisa Tidecks *Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0009-0006-9535-9586
Maria Wilhelm *Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Waleed ElGrawaniInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Sian DussNeuroscience Center Zurich (ZNZ), University of Zurich and ETH Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-0212-0324
Chiara TrevisanInstitute of Neuropathology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-3997-094X
Dalila VenaInstitute of Neuropathology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0009-0007-6863-7349
Anna Maria ReussNeuroscience Center Zurich (ZNZ), University of Zurich and ETH Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-1096-3030
Lucas KisslingInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-4989-0695
Matteo RanucciInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Mattia PriviteraNeuroscience Center Zurich (ZNZ), University of Zurich and ETH Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-5660-5901
Lisa K PolzerInstitute of Neuropathology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0009-0007-5279-0883
Athena E EconomidesInstitute of Neuropathology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-2340-6364
Eleonora I IoannidiInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0009-0008-3005-2684
Raquel MendesInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-3079-6647
Yanik WeberInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-0914-8541
Justine LeonardiNeuroscience Center Zurich (ZNZ), University of Zurich and ETH Zurich, Zurich, Switzerland.ORCID http://orcid.org/0009-0008-3555-5563
Jonas MumenthalerInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Elina VilligerInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Romain GoutagnyUniversity of Strasbourg, CNRS, LNCA UMR 7364, Strasbourg, France.ORCID http://orcid.org/0000-0002-1268-533X
Chantal MathisUniversity of Strasbourg, CNRS, LNCA UMR 7364, Strasbourg, France.ORCID http://orcid.org/0000-0002-6663-5282
Lukas SchmidheiniInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-5993-9985
Tanja RothganglInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Sharan JanjuhaInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-5910-2912
Tommaso PatriarchiInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-9351-3734
Johannes BohacekNeuroscience Center Zurich (ZNZ), University of Zurich and ETH Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-8442-653X
Yaroslav SychInstitute of Cellular and Integrative Neuroscience, CNRS UPR3212, University of Strasbourg, Strasbourg, France.ORCID http://orcid.org/0000-0002-1822-8631
Adriano AguzziNeuroscience Center Zurich (ZNZ), University of Zurich and ETH Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-0344-6708
Jochen WintererLaboratory of Systems Neuroscience, Institute for Neuroscience, Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-6800-6594
Konstantinos KompotisInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-4106-4062
Gerald SchwankInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland. schwank@pharma.uzh.ch.ORCID http://orcid.org/0000-0003-0767-2953

Funding

Alzheimer's Association E2A-23-1148138Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 179040Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 207872Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 310030_185293
6 · The paper itself

Abstract

Prime editing offers versatile genome modifications with therapeutic potential; yet its use to modulate neural circuitry remains underexplored. Here, we used adeno-associated viral vectors to deliver prime editors into the mouse brain and introduced the naturally occurring Adrb1

Indexed as

Alzheimer DiseaseBrainGene EditingReceptors, Adrenergic, beta-1Sleep, REMAdrenergic NeuronsAnimalsDependovirusDisease Models, AnimalGenetic VectorsHumansMaleMiceMice, Inbred C57BLMice, TransgenicReceptors, Adrenergic, beta-1

Identifiers

PMID41365977
PMCPMC12689628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.